Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...

BioNTech (BNTX) is presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA therapeutics, immunomodulators, and ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. In November, BioNTech agreed to acquire Biotheus, a clinical-stage ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...